Precision tumor immunotherapy via a dual-gated macrophage–bacterial activation platform
Trends in Biotechnology · 2026
DOI: 10.1016/j.tibtech.2025.09.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Biotechnology, 2026. Verfasst von Lin Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023. Jiangsu, PR China. Hauptthemen laut MEDLINE: Immunotherapy, Macrophages, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy based on live microorganisms has shown promise in preclinical studies, but its clinical translation has been hampered by limited efficacy and non-negligible toxicity. Here, we developed Macrophage-Bacteria encapsulation Lytic Autoactivated Synergistic Therapeutics (M-BLAST), a dual-gated macrophage-mediated bacterial tumor-targeted delivery and in situ activation system. M-BLAST incorporates density-regulated virulence-enhanced attenuated Salmonella strains as the therapeutic core, thermally controlled gasdermin D N-terminal fragment (GSDMD-N)-expressing macrophages as the delivery vector, and copper selenide, a photothermal material, as a heat shock 'primer'. Following systemic administration, localized near-infrared (NIR) irradiation at the tumor site triggers macrophage pyroptosis, ensuring rapid and complete bacterial release. This disrupts the immunosuppressive tumor microenvironment (TME) and elicits a widespread cascading antitumor response, just like a 'immune bomb', while the dual-gating design of bacterial density and heat shock ensures safety by preventing off-target activation in non-tumor regions. Thus, M-BLAST could enhance the therapeutic utility of living engineered bacteria for cancer while ensuring safety for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023. Jiangsu, PR China.
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023. Jiangsu, PR China; Nanjing Generecom Biotechnology Co., Ltd, Nanjing 210023, Jiangsu, PR China; Changzho…
- College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, National Laboratory of Solid State Microstructures, Nanjing University, Nanjing, 210023, Jiangsu, PR China.
- Faculty of Pharmaceutical Sciences, Xinxiang Medical University, Xinxiang 453002, Henan, PR China.
- College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, National Laboratory of Solid State Microstructures, Nanjing University, Nanjing, 210023, Jiangsu, PR China. Ele…
Förderung
- Innovative Research Group Project of the National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Changzhou Municipality
Zitieren
APA
Li, L., Wu, L., Qiao, L., Zhang, S., Luan, X., Qiu, J., Qiao, X., Li, C., Sun, Y., Wang, B., Du, Z., Chang, X., Zhuang, H., Zhang, T., Jia, Y., Wang, T., Ren, W., Song, Y., & Hua, Z. (2026). Precision tumor immunotherapy via a dual-gated macrophage–bacterial activation platform. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2025.09.013
Vancouver
Li L, Wu L, Qiao L, Zhang S, Luan X, Qiu J, et al. Precision tumor immunotherapy via a dual-gated macrophage–bacterial activation platform. Trends in Biotechnology. 2026. doi:10.1016/j.tibtech.2025.09.013
BibTeX
@article{Li2026,
author = {Li, Lin and Wu, Leyang and Qiao, Liyuan and Zhang, Shuhui and Luan, Xiaowei and Qiu, Jiahui and Qiao, Xinyue and Li, Chenyang and Sun, Ying and Wang, Bohao and Du, Zengzheng and Chang, Xiaoyao and Zhuang, Hongqin and Zhang, Tao and Jia, Yanlong and Wang, Tianyun and Ren, Wenjie and Song, Yujun and Hua, Zichun},
title = {Precision tumor immunotherapy via a dual-gated macrophage–bacterial activation platform},
journal = {Trends in Biotechnology},
year = {2026},
doi = {10.1016/j.tibtech.2025.09.013}
}
EUVIMED